Actelion receives FDA approval for 32mg Tracleer to treat paediatric PAH patients

Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson& Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patients with idiopathic or congenital pulmonary arterial …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news